ArticleMedicine2026
Epidemiological characteristics of serum small dense low-density lipoprotein cholesterol: From 2017 to 2019 in Chengdu adults, China.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Small dense low-density lipoprotein cholesterol is a better indicator in monitoring atherosclerotic cardiovascular disease. This study was designed to explore the distribution patterns of small dense low-density lipoprotein cholesterol (SdLDL-C), SdLDL-C/(low-density lipoprotein cholesterol [LDL-C]; SLR), SdLDL-C/(high-density lipoprotein cholesterol [HDL-C]; SHR), and SdLDL-C/(apolipoprotein B; SBR) in adults in Chengdu, China. The retrospective study enrolled 1549 adults (aged 20-69 years) in Chengdu, China from 2017 to 2019. The subjects were first divided into 5 age groups to evaluated the distribution patterns of SdLDL-C, SLR, SHR, and SBR in adults in Chengdu, China, then divided into normal and dyslipidemia groups to compare the differences, and multiple lipid parameters were quantitatively analyzed the differences further. Finally, we had evaluated the correlations among SdLDL-C, SLR, SHR, and SBR and other lipids. The median concentrations of serum SdLDL-C, SLR, SHR, and SBR were 0.71 mmol/L, 0.29, 0.54, and 0.83, respectively, in adults in Chengdu, China. The levels of serum SdLDL-C, SLR, SHR, and SBR increased with age. Men had higher levels of SdLDL-C, SLR, SHR, and SBR than women. The dyslipidemia group had higher levels of SdLDL-C, SLR, SHR, and SBR than the normal group. And in the subgroups of dyslipidemia, the differences in SdLDL-C, SLR, SHR, and SBR among subgroups were statistically meaningful. SdLDL-C, SLR, SHR, and SBR were positively correlated with total cholesterol, triglycerides, LDL-C, apolipoprotein B, and non-high-density lipoprotein cholesterol, whereas inverse correlations were observed with HDL-C and apolipoprotein A1. Our study showed the distribution characteristics of serum SdLDL-C, SLR, SHR, and SBR in adults in Chengdu, China, which contributed to the growing body of evidence supporting the incorporation of advanced lipid markers into cardiovascular risk assessment frameworks, particularly for Chinese populations with unique metabolic characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.